Patent cliffs kill revenue. Investors know it. What they often lack is a precise, well-sourced, actionable briefing that tells them […]
Own the Cliff: How Biopharma Data Providers Turn Patent Expiry Into Investor Revenue Read Post »
The global pharmaceutical industry is entering a period of wealth transfer that has no historical equivalent. Between 2025 and 2030,
Sell To Pharma Using Patent Timelines Read Post »
The $2 Billion Filing Error In March 2000, the USPTO denied a patent term extension application filed by Pfizer for
PTE Denied: The Rules That Kill Patent Term Extensions Before They Start Read Post »
The Name Behind the Molecule Every drug in clinical use has at least three names. There is the brand name,
The Drug Name Decoder: A Complete Guide to Generic Pharmaceutical Naming Read Post »
Section 1: The Strategic Calculus of a Paragraph IV Challenge The decision to initiate a Paragraph IV (Para IV) challenge
The pharmaceutical industry is entering a historic super-cycle of patent expirations between 2025 and 2030.1 During this window, an estimated
The Race Nobody Wins Every year, dozens of generic manufacturers file ANDAs for the same thirty drugs. They spend millions
Find the Gaps: How to Identify and Win Low-Competition Generic Drug Launch Opportunities Read Post »
The Forecast That Keeps Getting Wrong Every year, Wall Street analysts publish revenue forecasts for major pharmaceutical products that prove
The most profitable single legal filing in American commerce is not an M&A deal, a securities offering, or a licensing
Attack First: How to Challenge Drug Patents and Capture Market Exclusivity Read Post »
Sign in or create a free account to read this DrugPatentWatch article
